Ipsos vs ZoomRx: When Global Research Scale Works Against a US Pharma Launch

Ipsos is the world's third-largest market research company, with Global Therapy Monitors across 30+ disease areas and a presence in 87 countries. For global pharma companies needing standardized brand health measurement across many markets, that infrastructure is real. But global scale isn't an asset when you're six months into a US launch and need to know whether your promotional investment is moving physician perception before prescriptions drop off. For that problem, generalist infrastructure creates overhead where you need speed, and broad coverage creates distance where you need depth. Here's where those gaps show up.

What Ipsos Does Well

Ipsos Healthcare's breadth is real. Their physician panel spans a wide range of specialties across markets. Their Global Therapy Monitors provide ongoing syndicated data on disease-level treatment patterns. The Rx Insight Store offers on-demand access to reports and dashboards. For global programs requiring consistent methodology across multiple countries, or for syndicated disease tracking over time, Ipsos brings genuine infrastructure and experience.

Where the Structure Has Limits for US Launch Tracking

1. Pharma is a vertical inside a generalist firm, not an identity

At Ipsos, healthcare is one practice group among many, alongside consumer goods, automotive, public opinion, media, and financial services. The researchers working on your ATU program are part of a healthcare team within a general research organization. At ZoomRx, every researcher, every panel decision, every benchmark, and every line of platform code was built exclusively for pharmaceutical commercial research. The depth of institutional knowledge that accumulates from doing this and only this, knowing what a promotional recall score means in oncology versus immunology or what "trial" looks like in a biologics market versus primary care, doesn't transfer from other industries. It's earned.

2. No pharma-specific launch benchmark database

Ipsos's Global Therapy Monitors track disease-level treatment patterns over time. They aren't a launch performance benchmark database. They can't tell your brand team whether your 38% unaided awareness at T+3 is strong relative to comparable launches in your therapeutic area, because that comparison requires primary research benchmarks from actual ATU waves, not syndicated treatment data.

ZoomRx’s benchmark library covers 700M+ data points across 500+ pharmaceutical launches, matched by therapeutic area and time point. The difference between knowing your score and knowing what your score means is the difference between tracking and intelligence.

3. Separate research modules mean no traceable chain from promotion to prescription

Ipsos runs ATU brand tracking, promotional effectiveness, and patient chart research as independent programs, each with its own screener, physician sample, and timeline. Connections between them are made at the reporting stage.

The consequence is structural. You can't trace whether the physicians who saw your promotion are the same ones whose awareness shifted and whose prescribing followed, because the data was never collected from the same respondents. The most important question in launch intelligence goes unanswerable.

4. No voice-first research design

Ipsos's tracking research is quantitative-primary, with qualitative work commissioned as separate focus group or interview projects. ZoomRx's voice-first design embeds audio open-end responses directly within the quantitative survey, from the same physicians answering the same wave. Every wave of quantitative data comes with the qualitative "why" built in. That's a research design capability Ipsos's standard architecture doesn't support.

5. Global scale creates overhead, not advantage, for a focused US launch

Ipsos's global footprint is an asset for multinational programs. For a US-focused launch brand, that infrastructure creates overhead. Research design has to accommodate global standardization frameworks. Timelines are shaped by global coordination. Brand attention is distributed across a large, diversified portfolio. ZoomRx's proprietary panel of 60,000+ verified US physicians is profiled at the level of prescribing volume, patient mix, and access to specific drug classes. That enables rapid follow-up in days without any coordination layer.

6. No real-time AI access to live survey data

Ipsos has invested in dashboards, the Rx Insight Store, and data visualization tools. These are useful for accessing completed data. They don't offer anything equivalent to ZoomRx Answers, a tool that lets brand teams query their specific respondents' answers from the current wave in natural language, receiving metric breakdowns with verbatim voice clips within minutes of a wave closing. That's the difference between a reporting platform and a live intelligence capability.

Ipsos vs ZoomRx: Side-by-Side

The Question That Decides It

"Show me how promotional exposure in your research connects to physician perception, which connects to prescribing intent, which connects to what your chart audit data shows — all from the same respondent pool, in the same data environment."

Ipsos will show you brand tracking dashboards that aggregate survey data from separately recruited samples. We connect the data at the screener level, before any survey goes into field, so the entire chain is measured from a single physician pool, not reconstructed across separate studies.

For a US launch brand, pharma-specialist launch intelligence outperforms global generalist scale on every dimension that determines first-year performance.

Find out how your launch awareness, trial, and recall metrics compare against primary research benchmarks from 500+ comparable pharma launches.

Frequently Asked Questions